Based on recent clinical studies on monoclonal antibodies against MAdCAM-1 or α4β7 [45, 46], miR-29a-3p could be an effective therapeutic strategy for IBD treatment. The gene discussed is MADCAM1; the disease is inflammatory bowel disease.